Clinical Trial
Study Details
Enrollment
180
Phase
Phase 1
Primary Completion
Status
RECRUITING
Study Completion
Study ID #
NCT05661916
Study Start
Study Type
Interventional
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single ascending doses of ALN-TTRSC04.
Study Overview
Conditions
Participation Criteria
Eligibility Criteria
Inclusion Criteria:
* Body mass index (BMI) ≥18.0 kg/m\^2 and ≤30 kg/m\^2 assessed at Screening.
Exclusion Criteria:
* Has an estimated glomerular filtration rate (eGFR) \<90 mL/min/1.73m\^2 at screening.
* Has alanine aminotransferase (ALT), aspartate aminotransferase (AST) or direct bilirubin above the upper limit of normal (ULN).
Eligibility Maximum Age
65 Years
Eligibility Minimum Age
18 Years
Sexes Eligible for Study
ALL
Eligibility Std Ages
Adult
Older Adult